Yield10 Bioscience, Inc. (YTEN) Tops Q1 EPS by 1c

Yield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q1 EPS of ($0.22), $0.01 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $124 thousand versus the consensus estimate of $120 thousand.

"2019 is off to a strong start for Yield10 and holds the potential to be a pivotal year for the Company,” said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. “With more than 10 crop yield traits advancing in our pipeline, we continue to execute against our strategy to generate proof points in key commercial crops throughout 2019. We are also leveraging our 'Trait Factory' to drive collaborative opportunities with the objective of forming revenue generating partnerships to create a path to commercialization for our yield traits.”

“During the first quarter we completed the steps required to initiate planting for our 2019 Field Tests of C3003 and C3004, which we anticipate occurring in second quarter, pending suitable weather conditions. We also continued to make important progress deploying our novel yield traits for evaluation in canola, soybean, corn, wheat and rice, where in many cases we are leveraging third party capabilities and resources. We expect that many of these programs will produce agronomic and/or yield data during 2019, which should position Yield10 for future commercial opportunities,” Dr. Peoples concluded.

For earnings history and earnings-related data on Yield10 Bioscience, Inc. (YTEN) click here.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026